{"id":"W2120901491","doi":"10.1016/s1470-2045(12)70346-7","title":"Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial","year":2012,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":588,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"National Cancer Institute; Canadian Cancer Society Research Institute; Cancer Research UK; Chugai Pharmaceutical; Cancer Research Institute","keywords":"Medicine; Ifosfamide; Soft tissue sarcoma; Chemotherapy; Hazard ratio; Surgery; Radiation therapy; Clinical endpoint; Sarcoma; Internal medicine; Neutropenia; Doxorubicin; Randomized controlled trial; Oncology; Soft tissue; Etoposide; Confidence interval; Pathology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03809641802320107,"score_gpt":0.3435834134777455,"score_spread":0.3054869954545444,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}